Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections can cause loss or alteration of taste and smell as early symptoms or sequelae, but the detailed mechanism behind this phenomenon remains unclear. Here, we investigated whether the SARS-CoV-2 spike protein induces taste cell apoptosis and expression of the apoptosis-related cytokine TNF-α in male Sprague–Dawley rats. Terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate (dUTP)-fluorescein nick end labeling (TUNEL) assay results revealed a significantly higher apoptosis index for taste cells in the SARS-CoV-2 group than for those in the control group. An immunohistochemistry analysis indicated significantly more TNF-α-positive cells in the SARS-CoV-2 group compared with the control group. These data suggest that the SARS-CoV-2 spike protein promotes taste cell apoptosis and the release of apoptosis-related cytokine TNF-α, implicating its contribution to the taste malfunction caused by coronavirus disease 2019 (COVID-19).
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections cause loss or alteration of taste and smell as early symptoms and sequelae, but the detailed mechanism remains unclear. This study investigated whether coronavirus disease 2019-induced taste disorders are caused by direct effects on taste bud cells. SARS-CoV-2 recombinant spike and nucleocapsid proteins were applied to circumvallate papillae of male Sprague–Dawley rats. Immunohistochemistry and image analysis were used to compare the number of taste buds, and taste bud cells and area, together with confirmation of angiotensin-converting enzyme 2 (ACE2) expression. Immunohistochemical analysis revealed ACE2 expression in the taste buds of rat circumvallate papillae. Decreases in the number of taste buds, taste bud cells, and their area were observed at 12 days after application of SARS-CoV-2 recombinant spike and nucleocapsid proteins. These data suggest that SARS-CoV-2 proteins induce degeneration of taste buds.
Pheochromocytoma is an endocrine tumor characterized by abnormal catecholamine production. We report the anesthetic management of a 47-year-old woman with a history of familial bilateral pheochromocytoma and prior bilateral adrenalectomy, who underwent cyst enucleation under general anesthesia. The patient was on maintenance corticosteroid therapy and presented with suspected local recurrence. Given her adrenal insufficiency and history of hypertension, perioperative care required meticulous hemodynamic monitoring, stress-dose steroid supplementation, and avoidance of exogenous epinephrine. Anesthesia was induced with sevoflurane and remifentanyl, and intraoperative hypotension was successfully managed with ephedrine. Phentolamine was prepared in anticipation of potential catecholaminergic crises. The procedure proceeded uneventfully with stable hemodynamics and no complications. This case underscores the unique anesthetic challenges in managing patients with coexisting adrenal insufficiency and the risk of catecholamine excess. Careful perioperative planning is essential to ensure safety and hemodynamic stability.